Copyright
©The Author(s) 2018.
World J Transplantation. Sep 10, 2018; 8(5): 122-141
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.122
Published online Sep 10, 2018. doi: 10.5500/wjt.v8.i5.122
Table 5 Eculizumab dosing in atypical hemolytic uremic syndrome based on dosing goal, one additional monitoring may be required during intercurrent events (e.g., infection, surgery, vaccination) to detect unblocked complement activity
Minimal dose | Desire to continue dosing with the minimal dose required to achieve a pre-identified level of complement blockade 1 |
Dose reduction or interval extension | |
Goal CH50 < 10% (recommended) | |
Goal AH50 < 10% (recommended) | |
Goal eculizumab trough > 100 μg/mL | |
Discontinuation | Desire to discontinue complement blockade: No consensus exists regarding tapering of dose |
- Citation: Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141
- URL: https://www.wjgnet.com/2220-3230/full/v8/i5/122.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i5.122